Latest Intellectual Property News

Locksley Resources has partnered with Columbia University to develop cutting-edge, sustainable technologies for rare earth and critical mineral processing in the US, advancing its Mine-to-Market strategy amid growing government support.

Algorae Pharmaceuticals has announced a non-renounceable Loyalty Options Offer to eligible shareholders, aiming to raise up to $337,678 before costs, with potential additional capital of $4.7 million if all options are exercised. The capital raise supports the company’s pharmaceutical and AI research and development ambitions.

Energy World Corporation Ltd has outlined a strategic reset including a $442 million debt-to-equity conversion and is progressing towards commissioning its flagship Pagbilao LNG and power project in the Philippines, alongside advancing its Sengkang LNG facility in Indonesia.

WhiteHawk Limited has launched its first Australian office in Perth and signed a Memorandum of Understanding with Novera to co-develop a cybersecurity and AI governance platform tailored for the Australian market and broader APEC region.

Biotron Limited’s lead HBV drug BIT-HBV001 demonstrates superior antiviral activity and synergy with the current standard treatment Tenofovir in preclinical models, advancing hopes for a more effective Hepatitis B therapy.

Anteris Technologies Global Corp. reported a $22.2 million loss in Q3 2025 while progressing its DurAVR Transcatheter Heart Valve pivotal trial following key regulatory approvals. The company bolstered its cash position with a $25.2 million private placement post-quarter.

Orica Limited reported a 6% increase in revenue to AUD 8.14 billion and a 23% rise in EBIT to AUD 992.2 million for FY2025, alongside record safety performance and significant strides in decarbonisation.

BPH Global Ltd is pioneering a novel seaweed-based natural formulation targeting male vitality, staking a first-mover claim in this emerging segment of men’s health. The company’s R&D, led by Gaia Mariculture, aims to launch an OTC supplement with potential for clinical validation.

dorsaVi Limited has acquired a cutting-edge neuromorphic processing-in-memory technology portfolio, positioning itself at the forefront of next-generation wearable and robotics intelligence. This strategic move, coupled with leadership changes, signals a new era for the company’s adaptive biosensor and robotics platforms.

Pathkey.AI has teamed up with Armstrong Clinical to blend AI-driven trial predictions with expert clinical strategy, aiming to boost early-phase trial success and accelerate drug development in Australia and beyond.

Aristocrat Leisure reported robust FY25 results with 11% revenue growth to A$6.3 billion and a 12% rise in NPATA, fueled by strong performances across its gaming segments and strategic acquisitions. The company signals continued profit growth in FY26, underpinned by organic expansion and market share gains.

Aristocrat Leisure reported robust FY25 results with revenue up 11% to $6.3 billion and a 12% rise in normalised net profit after tax before amortisation. The company boosted dividends by 19% and completed key acquisitions and divestitures, positioning itself for future growth.